Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 1 2Phase NA 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Glioblastoma 60Carcinoma, Non-Small-Cell Lung 47Lung Neoplasms 38Head and Neck Neoplasms 26Gliosarcoma 26Squamous Cell Carcinoma of Head and Neck 25Pancreatic Neoplasms 25Central Nervous System Neoplasms 23Rectal Neoplasms 21Brain Neoplasms 21Breast Neoplasms 17Astrocytoma 17Sarcoma 16Neoplasms 16Glioma 15Uterine Cervical Neoplasms 14Prostatic Neoplasms 14Esophageal Neoplasms 14Carcinoma, Squamous Cell 11Lymphoma, Follicular 10Leukemia 10Melanoma 9Lymphoma, Large B-Cell, Diffuse 9Lymphoma 9Leukemia, Lymphocytic, Chronic, B-Cell 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 8Lymphoma, Non-Hodgkin 8Neoplasm Metastasis 7Myelodysplastic Syndromes 7Lymphoma, Mantle-Cell 7

Interventions

aflutinib 3osimertinib 2Radiotherapy 2tipifarnib 1apatinib 1Radiosurgery 1Immune Checkpoint Inhibitors 1Gefitinib 1Docetaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1 × NSCLC × Radiotherapy × Clear all
NCT05615142 2026-05-11

Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.

Sichuan University

Phase 1 Active not recruiting
9 enrolled
Thoracic

NSCLC

NCT05222087 2024-08-15

PRIME_LUNG

Peter MacCallum Cancer Centre, Australia

Phase 1 Recruiting
40 enrolled
Thoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡